Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.55 |
| ▸ | CES2 | O00748 | 3/20 | 0.54 |
| ▸ | RXRA | P19793 | 2/20 | 0.52 |
| ▸ | RXRB | P28702 | 2/20 | 0.52 |
| ▸ | RXRG | P48443 | 2/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.49 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.47 |
| ▸ | VNN1 | O95497 | 2/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30770849 | 1.00 | HCAR1 (0.55) | HCAR1CES2RXRARXRBRXRG | |
| Hydrochloric Acid SCHEMBL12097700 | 0.98 | HCAR1 (0.53) | HCAR1CES2RXRARXRBRXRG | |
| SCHEMBL545011 | 0.87 | CES2 (0.62) | CES2RXRARXRBRXRGSRD5A2 | |
| SCHEMBL503980 | 0.87 | CES2 (0.70) | CES2RXRARXRBRXRGSRD5A2 | |
| SCHEMBL27757817 | 0.85 | CES2 (0.56) | CES2RXRARXRBRXRGSRD5A2 | |
| Hydrochloric Acid SCHEMBL7485970 | 0.85 | CES2 (0.67) | CES2RXRARXRBRXRGSRD5A2 | |
| SCHEMBL28119413 | 0.85 | CES2 (0.67) | CES2RXRARXRBRXRGSRD5A2 | |
| SCHEMBL1827001 | 0.83 | CES2 (0.54) | CES2RXRARXRBRXRGVNN1 | |
| SCHEMBL679313 | 0.82 | CES2 (0.52) | CES2RXRARXRBRXRGVNN1 | |
| SCHEMBL30437904 | 0.82 | CES2 (0.52) | CES2RXRARXRBRXRGVNN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 363 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025202864-A1 | ENT1 INHIBITORS IN COMBINATION WITH ONCOLYTIC VIRUSES AND THEIR USE IN THE TREATMENT OF CANCER | iTeos Belgium SA (BE) | 2025-10-02 | — | — | WO | claimed |
| WO-2025126110-A1 | ENT1 INHIBITORS IN COMBINATION WITH BISPECIFIC ANTIBODIES | iTeos Belgium SA (BE) | 2025-06-19 | — | — | WO | claimed |
| WO-2025104613-A1 | ENT1 INHIBITORS IN COMBINATION WITH CHECKPOINT INHIBITORS | iTeos Belgium SA (BE) | 2025-05-22 | — | — | WO | claimed |
| CN-119431706-A | Fatigue-resistant polyurethane elastomer and preparation method and application thereof | 万勋科技(深圳)有限公司 | 2025-02-14 | — | — | CN | claimed |
| CN-116535365-A | Macrocyclic diamine derivatives and their combination with adenosine receptor antagonists as ENT inhibitors for the treatment of cancer | ITEOS比利时公司 | 2023-08-04 | — | — | CN | claimed |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-06-29 | — | — | US | claimed |
| EP-4132933-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | iTeos Belgium SA (BE) | 2023-02-15 | — | — | EP | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-107681052-B | Main group metal complexes as p-dopants for organic electronic matrix materials | 西门子公司 | 2020-03-24 | — | — | CN | claimed |
| US-10483466-B2 | P-doping cross-linking of organic hole transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2019-11-19 | — | — | US | claimed |
| EP-3114715-B1 | P-DOPING CROSS-LINKING OF ORGANIC HOLE TRANSPORTERS | SIEMENS AG (DE) | 2019-10-30 | — | — | EP | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| US-20180198069-A1 | P-Doping Cross-Linking Of Organic Hole Transporters | SIEMENS AKTIENGESELLSCHAFT (DE) | 2018-07-12 | — | — | US | claimed |
| EP-3057151-B1 | BISMUTH AND TIN COMPLEXES AS P DOTANDS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | SIEMENS AG (DE) | 2018-01-31 | — | — | EP | claimed |
| US-20170098787-A1 | MAIN GROUP METAL COMPLEXES AS P-DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | SIEMENS AKTIENGESELLSCHAFT (DE) | 2017-04-06 | — | — | US | claimed |
| EP-3057151-A1 | PRINCIPAL GROUP METAL COMPLEXES AS P DOTANDS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | Siemens Aktiengesellschaft (DE) | 2016-08-17 | — | — | EP | claimed |
| US-8853619-B2 | Method for detecting tracer compounds for hydrocarbon production | TOTAL S.A. (FR) | 2014-10-07 | — | — | US | claimed |
| US-20110260051-A1 | METHOD FOR DETECTING TRACER COMPOUNDS FOR HYDROCARBON PRODUCTION | TOTAL S.A. (FR) | 2011-10-27 | — | — | US | claimed |
| US-20260125374-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF MAKING AND USING THE SAME | RELAY THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-0612723-A1 | Substituted benzoylguanidines, process for their preparation, their use as medicament, as inhibitor of the cellular Na+/H+ exchange or as diagnostic agent and medicament containing them | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-08-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170098787-A1 | MAIN GROUP METAL COMPLEXES AS P-DOPANTS FOR ORGANIC ELECTRONIC MATRIX MATERIALS | SCO2, SOD3, NCOA3 | HCAR1 2787/4885CES2 3153/4885RXRA 331/4885 |
| US-20230203058-A1 | MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS | ENTPD1, SLC29A1, ENTPD5 | HCAR1 136/4885CES2 4086/4885RXRA 1817/4885 |
| US-20260125374-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF MAKING AND USING THE SAME | PIK3CD, PI4KA, PIK3C2A | HCAR1 4766/4885CES2 4139/4885RXRA 3426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.